Jump to content


  • Posts

  • Joined

  • Last visited

beejeboi's Achievements


Newbie (1/14)

  • Collaborator Rare
  • First Post Rare
  • Week One Done Rare
  • One Month Later Rare

Recent Badges



  1. We've seen a lot of positive announcements by the group. Give this a read https://prophet-invest.com/askari-metals-next-big-copper-gold-explorer
  2. Should I Buy Macquarie Bank Shares? Highlights MQG Share Price Much like the rest of the market MQG shares have now fully recovered from the COVID Crash, and are now pushing all-time highs. At the time of writing MQG is priced at $153.71. Their share price is up 10.72% over the last 6-months and up 22.79% over the last 12 months. These results are largely in line with the market average being up 21.73% in the last year. MQG has dropped off slightly from its all-time high in May, their 52-week range is 118.36-162.06. Its current market capitalization is $56.6 Billion. Over the past 10-years, MQG has made excellent returns for investors with their share price increasing 466.92%. Each year the share price has made an average gain of 41.66%, while also averaging a dividend yield of 15.04% over a ten-year period. Investors have enjoyed a 56.70% return averaged over the long term. About Macquarie Group is an international company in the financial services space. They operate in 32 markets in asset management, retail and business banking, wealth management, leasing and asset financing, market access, commodity trading, renewables development, specialist advisory, capital raising, and principal investment. Macquaries Businesses: Macquarie Asset Management – A top 50 global asset manager, managing over $495 billion of assets on behalf of superannuation funds and other institutional investors Macquarie Asset Management oversees three stand-alone businesses: Macquarie Infrastructure and Real Assets (MIRA) Macquarie Investment Management (MIM) Macquarie Specialised Investment Solutions (MSIS) Banking and Financial Services – This is Macquarie’s retail banking business that provides personal banking, wealth management, and business banking products. There are two capital markets facing businesses: Commodities and Global Markets – Conducts market research on behalf of clients covering equities, derivatives, fixed income, foreign exchange, and commodities. Macquarie Capital – Advisers and facilitates the listing of companies on the share market, and provides other Investment banking services. Macquarie Asset Management (MAM) and Commodities and Global Markets (CGM) are by far the most profitable ventures for Macquarie, each generating over $2 Billion in profits over the FY21. Dividend History MQG shares typically announce a dividend with the release of its half-yearly results in November and full-year results in May as seen in their financial calendar. Dividends are typically paid twice a year, in July (Final Dividend) and December (Interim Dividend). The current average yearly dividend for MQG shares is $4.70 giving them a solid net yield of 3.07% or a gross yield of 3.59% at the current share price. Financials In May MQG released its Full Year FY21 report. The group lists the following highlights: FY21 net profit of $A3,015 million, up 10% on FY20; 2H21 net profit of $A2,030 million, up 106% on 1H21, up 59% on 2H20 International income representing 68% of total income AUM of $A563.5 billion, down 6% Financial position comfortably exceeds regulatory minimum requirements Group capital surplus of $A8.8 billion Bank CET1 Level 2 ratio 12.6% (Harmonised: 16.2%) Annualised return on equity of 14.3%, compared with 14.5% in FY20 Macquarie Group’s profit of $3 Billion, represents their largest profit to date. Current Broker Views Citi: Sell, Target Price: $140 Macquarie’s acquisition of AMP Capital’s global equities and fixed income business (GEFI) adds a further $60bn of funds under management (FUM), lifting Macquarie Asset Management’s (MAM) total FUM to $720bn. Citi expects no earnings contribution in FY22 with a minor benefit in FY23/24. Forecast: Citi forecasts a full year FY22 dividend of 520.00 cents and EPS of 797.40 cents. Citi forecasts a full year FY23 dividend of 540.00 cents and EPS of 808.60 cents. Morgan Stanley: Overweight, Target Price: $175 The acquisition of GEFI will add further diversity, scale, and relationships in the A&NZ market. Forecast: Morgan Stanley forecasts a full year FY22 dividend of 550.00 cents and EPS of 845.00 cents. Morgan Stanley forecasts a full year FY23 dividend of 605.00 cents and EPS of 908.00 cents. Morgans: Add, Target Price: $171 MQG’s full-year profit beat Morgans estimates. Morgans are expecting a flattish result for FY22, with positive results from the Macquarie Capital (MC) and bank. Forecast: Morgans forecasts a full year FY22 dividend of 526.00 cents and EPS of 832.40 cents. Morgans forecasts a full year FY23 dividend of 590.00 cents and EPS of 918.00 cents. Prophet’s Take Macquarie Group has performed very strongly during the economic downturn. Their strong balance sheet has allowed them to act in this time and grow their portfolio by acquiring AMP Capital’s global equities and fixed income business (GEFI), this has added $60 Billion of funds under management (FUM). Their ability to respond and grow profits to all-time highs has proven the long-term ability of MQG. We are bullish on MQG. Full Analysis: https://prophet-invest.com/should-i-buy-mac...rie-bank-shares
  3. Should I Buy Computershare 2021? Highlights Computershare managed to maintain its dividend despite the COVID recessions. Their fundamentals are largely in line with market standards, and their technical factors look good. We’re considering CPU shares in range, here’s why. Share Price Computershare has largely recovered from the COVID crash, which plummeted the share price by over 50%. The current CPU share price is $17.10, which is up 32.71% over the last 12-months. CPU is sitting in the upper end of its 52-week range of 11.75-17.49. Over the course of ten years CPU shares are up over 94.35%, proving to be a decent holding for long-term investors. About CPU provides Issuer Services, Mortgage Services & Property Rental Services, Employee Share Plans and Voucher Services, Business Services, Communication Services, and Utilities and Technology Services. Most shareholders should recognize their brand as the share registry for a large portion of ASX-listed companies. Dividend History CPU has paid biannual dividends every year since 1994. This includes the 2008 GFC and COVID recession. CPU shares pays dividends that are either fully franked, 30% franked, or unfranked dividends. The current average yearly dividend for CPU shares is $0.46 giving them a decent yield of 2.69% or a gross yield of 3.45% at the current share price. Note CPU shares are currently paying out all earnings to shareholders, this is unsustainable. Going forward we expect dividend payments to decrease as CPU targets a sustainable payout ratio closer to 50%. Fundamental Summary CPU is the 50th largest ASX listed company. Its PE is greater than the market average of 15-20x. Their PEG also demonstrates poor value. Their ROE is in line with the market average of 11%. CPU has a significant amount of debt at $2.154 billion. Earnings Guidance Upgrade CPU has upgraded their Management EPS to be down around 8% (previously down around 11%) For CPU FY21 expect: - Management EPS to be down by around 8% - Management EPS for 2H21 to be around 30.0 cents per share - EBIT ex Margin Income to be up by around 14% Key Assumptions › Margin Income revenue expected to be around $105m › Equity and interest rate markets remain at current levels / in line with current market expectations › Group tax rate between 28.0% – 30.0% › For constant currency comparisons, FY20 average exchange rates are used to translate the FY21 earnings to USD3 Following this they have projected a complete recovering to earnings by 2H21. Cashflow Statement From the cash flow statements, we can see receipts from customers have reduced slightly, while payments to suppliers and employees, loan servicing’s and income tax have all increased significantly. This has dramatically impacted the net operating cash flows of the business. We can see the company has significant debt, with high repayments yet managed to pay out 87.6M in dividends to shareholders. We appreciate the company trying to avoid cutting dividends. But at the height of the recession, almost all companies reduced their dividends to maintain a strong cash position. With CPU’s high debt levels the cash could have been deployed more appropriately to other uses. Computershare VS Link Market Services: The Duopoly Link Market Services is the other big player in the ASX share registry space. They are also a listed company under the ticker code ASX: LNK. These have a duopoly over the Australian market commanding an 86.5% market share. The share registry space works in typically 3 year contracts, and a smaller number of 1-2 year and over 5 year contracts. In recent years there has been an erosion in market share for market leader Computershare to the benefit of Link Market Services and smaller competitors. In 2016 CPU commanded a 57% market share of the ASX 200, and a combined 96%. Today CPU services 47.4% and the duopoly occupy 86.5% CPU’s Acquisition Of Wells Fargo Corporate Trust Services Back in March CPU announced the Acquisition of the assets of Wells Fargo Corporate Trust Services, a leading US based provider of trust and agency services to government and corporate clients The Acquisition is expected to generate attractive financial returns for shareholders. The purchase price of US$750m represents an EV/LTM EBITDA acquisition multiple of 8.9x (pre synergies). After including stand-up Capex, regulatory capital requirements, and full run-rate synergies it represents an EV/LTM EBITDA acquisition multiple of 5.9x Based on ongoing organic growth and cost savings, there is a clear pathway to CTS generating a return of over 15% on invested capital by FY252F. In order to fund this acquisition CPU undertook a major capital raising in march. The Institutional Entitlement Offer raised approximately A$500 million at the offer price of A$13.55 per new share. They also conducted a retail raise. The retail component of the Entitlement Offer is expected to raise A$335 million taking the expected size of Computershare’s total equity raising to approximately A$835 million. Prophet’s Take Computershare has an excellent synergy of businesses, with their added acquisition in the Wells Fargo deal we should see some excellent growth from CPU shares over the next five years. They are also expected to be return earnings to Pre-COVID levels in the second half of the year. At the time of writing, we don’t see the companies fundamental as anything to be excited about. They also have a large amount of poorly serviced debt and have chosen to pay a dividend whilst simultaneously increasing debt and raising capital. We believe that CPU’s share price is currently in-Range for the next 12months. How I DD a stock: https://prophet-invest.com/stock-dd-checklist-for-beginners Full Analysis if interested: https://prophet-invest.com/should-i-buy-computershare
  4. Should I Buy Flight Centre Shares 2021 Highlights Full Analysis Flight Centre’s share price has been bid down massively following the COVID pandemic. This saw the share price crash a massive 85.92%. Does the current discount present a buying opportunity to investors? About Flight Centre Shares FLT’s Principal Activity is travel retailing in both the leisure and corporate travel sectors, plus in-destination travel experience businesses including tour operations, hotel management, destination management companies (DMCs), and wholesale. Source: Market Index FLT ASX Share Price Just prior to the COVID recession Flight Centre shares had performed well pushing to an all-time high of 75.13 in August of 2018. Today the Flight Centre share price is $15.24, which is in the middle of its 52-week range of 9.76-20.16. This is still down around 80% since its peak. It’s up 6.57% this year. In comparison, the broader market is up 27.56% this year and has fully recovered from the recession pushing it to new heights. Should I Buy Flight Centre Shares: Financials half yearly results: THE Flight Centre Travel Group (FLT) continues to respond to the challenges posed by COVID19 and the unprecedented travel restrictions that are in place to slow its spread. In releasing its 2021 fiscal year (FY21) first half (1H) accounts, FLT said today that while global trading conditions remained volatile, results had gradually improved thanks to targeted cost base reductions and revenue increases during the period. Since the crisis escalated in March 2020, the company has now: Lowered its cost base by 66% (representing a $1.9billion annualized saving) without jeopardizing either its investment in key growth drivers or its ability to rebound quickly when conditions improve Continued to generate total transaction value (TTV) and revenue in a prevaccination, domestic-only travel world – December revenue was at its highest point since travel restrictions were introduced globally in March 2020 Delivered month-on-month reductions in net operating cash outflow during the 1H; Maintained a $1.2billion liquidity runway to help it withstand an extended downturn or capitalize on opportunities during the recovery phase, which could now be fast-tracked with the world’s largest-ever vaccination program underway Should I Buy Flight Centre Shares: Technical Analysis The general consensus within the Technical Analysis community is currently bearish on FLT shares. The moving averages and Technical Indicators seem to indicate a Strong Sell. FLT Shares: Cap Raise and Bail Outs In the midst of the recession Flight Centre was desperate to get a piece of the government $1.2 Billion bailout. With little to no government aid FLT managed to bail themselves out with a capital raise announced in April 2020. Here are the details: •A ~$700 million fully underwritten equity capital raising, comprising a ~$282 million institutional placement (Placement) and a ~$419 million 1-for-1.74 accelerated pro-rata non-renounceable entitlement offer (Entitlement Offer) (together, the Equity Raising); •A $200 million increase in commitments from existing lenders Confirmation that the previously announced cost control initiatives and cash preservation initiatives are anticipated to reduce annualised operating expenses by approximately $1.9 billion2 (to approximately $65 million per month, by the end of July 2020). This placment was largely successful raising approximately A$562 million at A$7.20 per New Share. The Travel Sector Crash The travel sector has realized massive losses over the past year. With the three big-name brands (QAN, FLT, WEB) now being available at discounts of around 30-50%, while the market has largely recovered, investors are starting to see opportunity in these stocks that have been left behind. For the foreseeable future international table is off the tables. The latest federal budget has indicated that Australia is likely to be closed off from international travel until at least mid-2022. Flight Centre Shares: Future Prospects At this stage, the future prospects are obviously unclear. From the above statics, we clearly see the international travel sector has died for the foreseeable future. On the other hand, we are starting to see a strong recovery in domestic travel. FLT is relying on this strong return as they have significant exposure to domestic/regional travel. “FLT is targeting a return to breakeven in both leisure and corporate travel during the 2021 calendar year on the basis that domestic borders are likely to open permanently and some (low risk) international travel may be permitted” The return of domestic travel has had a positive impact on the return on revenues as bookings are returning. Full Analysis if Interested https://prophet-invest.com/should-i-buy-flight-centre-shares Here Once Again, Thanks for reading
  5. Should I Buy CSL Shares 2021 Highlights Full Analysis CSL Shares Price Today In November of 2020, CSL reached its all-time high with a share price of 320.42. The CSL share price did not respond to the COVID crash and continued higher as the rest of the market fell. Today the share price is 305.52. This is at the upper quartile of its 52-week range of 242-320.42. Over the past ten years, CSL is up over 810%. During this time it’s returned a breathtaking 91.09% each year. That’s 85.5% attributed to capital gains and 5.6% to its dividend return over this period. This has far outperformed the market’s total return of 64% over the same period. About CSL Shares CSL operates in three core areas; CSL Behring (Plasma): This area is the largest revenue driver for the company. They are responsible for the collection and refinement of blood and blood plasma products (namely immunoglobulin and albumin). CSL Plasma is the largest collector of human blood plasma in the world. They produce a range of life-saving medicines for critically ill patients. From burns treatments to transfusions Seqirus: Seqirus is one of the largest influenza vaccine companies in the world they manufacture and distribute of influenza vaccines annually. CSL Behring: The final segment makes up a small portion of CSL’s business. CSL Behring also develops different treatments and drugs for rare diseases, and many Australian anti-venoms. These three core strategies have an excellent synergy that makes CSL an excellent business. Privatization of CSL Shares In 1994, the Commonwealth facility was privatized as CSL Ltd. and was publicly listed and traded on the ASX. The company completed its IPO in June 1994 at just $2.30 per share. Dividend History CSL typically announces a dividend with the release of its half-yearly results in February and full-year results in August as seen in their financial calendar. Dividends are typically paid twice a year, in March (interim dividend) and September (final dividend). CSL has paid biannual dividends every year since 2009. CSL does not pay a franked dividend. The current average yearly dividend for CSL shares is $2.887 giving them a yield of 0.92% at the current share price. Fundamental Summary In terms of fundamentals, CSL shares are relatively overvalued. Their PE multiple of 38.22 is far above the market average of 15-20x. Of course, this could be interpreted as high investor sentiments for the growth of CSL. Here’s how to interpret PE Their PEG also reflects poor value. The company also has a very low book value of just $17.13 compared to its share price of $305. To support their valuation the company does have an amazing ROE of 27% compared to the market average of only 12.9%. CSL has continuously delivered results and as such has developed a relatively high earnings multiple. Technicals The general consensus within the Technical Analysis community is currently Bullish on CSL shares. The moving averages and Technical Indicators seem to indicate a Strong Buy. In summary, the upside is likely to prevail as long as $293 is supported. The alternative scenario is that a downside breakout of $293 would call for $286 and $283. Insider Ownership and Trading CSL has insider ownership of 0.1%. Meanwhile, general investors own the majority 71.7%, and institutions own 28%, and the remaining 0.2% are owned by private companies. The lack of insider ownership may seem like a red flag, however, it is important to recognize that CSL is an ex-government-owned business that has been privatized. We see that all privatized companies have the same proportion of ownerships as CSL, this includes CBA, TLS, TAH, QAN, SYD, SUN. Here’s a report by the RBA if you’re interested in privatization. There has been some minor insider buying activity in 2021. Around $230 million in shares have been purchased by insiders in the past six months. COVID Vaccine CSL is contracted to locally produce AstraZeneca COVID vaccines. With the company hoping to produce 50 million doses by the end of the year. CSL is capable of producing 1 million doses per week. With hopes of increasing productivity The Funded Deed with the Australian Government and CSL to manufacture AZD1222 vaccine is worth an undisclosed sum but estimated at around $1 billion. It’s difficult to estimate how much CSL will profit from their COVID-19 partnership. Although Seqirus their Influenza vaccine subsidy has profited substantially, with sales up 38 percent to $US1.4 billion amid global demand for influenza vaccines in the face of the COVID-19 pandemic. CSL Competitive Advantage CSL operates in the healthcare sector. Their vaccine and therapies are essential to healthcare and are immune to recessionary periods which was illustrated in 2008 and again during the COVID recession. Their strong balance sheet allows for the manufacture of new products and extensive R&D. From which they have the ability to generate positive operating cash flows and net profit. They don’t depend on investor’s capital. They are an essential business to the Australian economy and general population. They are essential to the future of the country and will continue to be supported by the government Should I Buy CSL Shares: Prophet’s take CSL is a resilient business essential to the health of the Australian and larger global communities. They have shown the ability to withstand several recessionary periods and have made impressive long-term gains for shareholders. The synergies of their business have allowed CSL to be a massive global healthcare player. This has also allowed the business to grow rapidly and respond quickly to the COVID pandemic, all while utilizing its strong balance sheet without the need for investor capital. The current technical factors indicate a strong buy, and given the excellent business model, a premium is to be expected on CSL fundamentals. We are currently BULLISH on CSL shares. Full article Prophet Invest Thanks for reading
  6. Should I Buy Sonic Healthcare Shares 2021? Highlights Full Analysis Share Price Over the past year, Sonic healthcare is up 30.92% and has more than recovered from the COVID-19 recession pushing to new all-time highs. The current sonic healthcare shares price is $37.81, at the upper end of its 52-week range of 28.53-38.39. Over the course of the past ten years, SHL is up 637%, averaging 50.63% per year. This is attributed to 42.26% in capital gains and 8.38% from its historically lucrative dividend yield. About Sonic Healthcare is the market leader in laboratory medicine/pathology in Australia, Germany, Switzerland, the UK, and Northern Belgium (Flanders), and the third-largest private laboratory company in the US. Sonic Imaging is the second largest diagnostic imaging provider in Australia. Sonic Imaging is made up of eight practice groups, with more than 100 radiology centers geographically spread across Australia. Sonic Clinical Services (SCS) brings together a broad spectrum of health services Dividend History SHL has paid biannual dividends every year since 1996. This includes the 2008 GFC and COVID recession. SHL pays a 20-30% franked dividend. The current average yearly dividend for SHL shares is $0.9819 giving them a decent yield of 2.3% or a gross yield of 2.6% at the current share price. Fundamental Summary The fundamentals indicate that SHL is reasonably priced. The PE of 18.94x is within the market average of 15-20x. SHL also has a relatively good ROE of 16.4%. The business debt to equity ratio is relatively high at around 42%. Financials Sonic Healthcare released it’s last full-year results in August 2021, here’s the highlights: FY2019 result in line with guidance – underlying EBITDA growth 6.7% (constant currency) Revenue growth 11.6% to A$6.2 billion EBITDA growth 13.3% to A$1.1 billion Net profit growth 15.6% to A$550 million Final dividend up 4.1% to $0.51 per share (full-year dividend up 3.7% to A$0.84) Strategic acquisition of Aurora Diagnostics completed in January 2019 Strategic divestment of non-core GLP Systems completed in June 2019 Growth momentum strong – major opportunities ahead Technicals The general consensus within the Technical Analysis community is currently Bullish on SHL shares. The moving averages and Technical Indicators seem to indicate a Strong Buy. In summary, the upside is likely to prevail as long as $36.8 is support. The alternative scenario is that a downside breakout of $36.8 would call for $35.7 and $35.1. Insider Ownership And Trading Sonic healthcare has no significant insider ownership, accounting for only 0.7%. The general public and institutions are the major shareholders owning 61.6% and 32.9% respectively. Private companies own 4.4% and the remaining 0.4% is owned by 0.4%. Veritas and Blackrock are the substantial shareholders in Sonic Healthcare. In 2021 there has been substantial trading activity in SHL. There has been slightly more selling, although nothing alarming to us. Sonic Healthcare And The COVID Recession At the beginning of the pandemic the company was materially impacted and responded with executives taking a 50 percent pay cut, a hiring freeze, and thousands of staff stood down. This large impact was mostly from the halt of routine testings during the beginning of the pandemic. Although portions of Sonic dropped during the COVID pandemic, the company as a whole is positioned well to grow coming out of the pandemic. Not only is it back to business as usual but they are one of the key players in testing for COVID-19 across several counties. For instance, their United States business, which makes up 27 percent of sales, is set to gain a piece of the spend of $US1.6 billion to expand COVID-19 testing. CEO Dr Goldschmidt said it could double or triple its testing if needed. Sonic is the world’s third-largest provider of clinical laboratory services and is the largest private pathology operator in Australia. Sonic’s position is secure and trends are looking positive at the company and business level CEO, Dr Goldschmidt Future Prospects Sonic Healthcare released the following outlook: Expect demand for COVID-19 testing to continue into the foreseeable future, volumes unpredictable Increasing acquisition, contract, and joint venture growth opportunities Supported by a very strong balance sheet, leaving sonic in a position for the strong future growth Currently bidding on significant opportunities in Australia, UK, USA, and Alberta, Canada Geographical diversification, providing increased opportunities for expansion Underlying strong healthcare growth drivers unchanged Leading market positions in Australia, Germany, USA, UK, Switzerland Sonic provides essential healthcare services, base business increasingly resilient to impacts of a pandemic. We see the companies operation to benefit and show continued growth following on from the pandemic. The companies history of strategic acquisitions has and will continue to make them a core healthcare provider across multiple countries. These acquisitions have and will continue to be a core business strategy for Sonic. Full Analysis: https://prophet-invest.com/should-i-buy-son...are-shares-2021 Thanks for reading
  7. Should I Buy Lendlease Shares 2021 Highlights Full Analysis About Lendlease Shares 2021 Lendlease is a globally integrated real estate and investment group with core expertise in shaping cities and creating strong and connected communities. Being bold and innovative characterises our approach and doing what matters defines our intent. Headquartered in Sydney, our people are located in four operating regions: Australia, Europe, the Americas and Asia ASX:LLC Share Price On the 5-year price performance chart, Lendlease Shares have been relatively sideways moving, however reaching an all-time high back in mid-2019, before falling back down to ~$12.5/share over the proceeding six months. Today the Lendlease share price is $12.165, which is in the middle of its 52-week range of 10.73-14.89. ASX:LLC Shares Dividend History Lendlease shares typically announce a dividend with the release of its half-yearly results in February and full-year results in August The dividend yield of LLC is 1.46%. Fundamentals there seems to have been a large slowdown of revenue and an even greater drop-off in earnings from FY2019 – FY2020. Looking at the groups EBIDTA this has taken a substantial impact since reaching all-time highs in 2018 over A$1billion. This seems to be largely attributed to the groups underperforming engineering business projects on the NorthConnex, Kingsford Smith Drive and Gateway Upgrade including what is also looking to face similar circumstances in their Joint Venture on the Melbourne Metro Project. ASX:LLC As A Development Arm: Lendlease highlight the requirement of increasing capital expenditure however also expecting a larger development production from invested capital moving forwards. This is largely due to their renewed focus on city building in massive pipeline communities, where they should be able to get economies of scale due to the size of the developments and favourable operating conditions. ASX:LLC As An Investment Company Lendlease is significantly growing its investment arm, from a total Funds under management in FY2010 of A$10billion to a Funds under Management in FY2020 of over A$36billion. The group also seems to have this decently diversified across Australia, Asia, Europe and the Americas. Lendlease Construction Arm: If the picture here isn’t very clear yet, the future aim of Lendlease can pretty much be summed up in our opinion as an “end-to-end, city builder” (ETECB), where they will secure and redevelop large parcels of land under favourable conditions and contracts. The building division is there to construct these developments, under once again favourable conditions. The EBIDTA margin on the construction division is typically much lower than their other businesses in investment and development as this is a very traditional business with a large amount of players. Departure Of The CEO And CFO On the 26th of November 2020, the group announced the departure of the companies CFO (Tarun Gupta). Tarun will leave the Group. Mr Gupta has accepted the role of Managing Director and Chief Executive Officer of Stockland. Whilst this seems like a logical step for the CFO to take it raises questions when only months later the groups CEO Steve McCann Announces his resignation. Steve McCann has since moved on to lead Crown Resorts as their CEO. This only raises the question, that if the CFO was in the know surely he would have been a front runner to step up into Steve’s shoes on a much larger salary than he would be on at Stockland Group. There may be nothing more around this, however, the timing seems a little strange. Full Artilce if Interested Thanks again
  8. What’s Going on With Bigtincan? Highlights https://prophet-invest.com/bigtincan-share-price"" target="_blank">Full analysis
  9. ASX Shares 2021 Highlight: It’s fair to say the ASX has a monopoly over Australian listed Investing. Yeah there’s the Chi-X, But ASX is no doubt the biggest and arguably only name in the game. ASX Shares Prices The ASX Ltd Share price is currently $76.43, down -13.73% over the course of a year. ASX shares have proven to be an excellent long term investment, averaging 14.4% pa The ASX Monopoly on Market Share It’s no question the ASX is winning the monopoly of Australian security and derivative trading. However, CHI-X has grown rapidly from 0% claiming 18% volume, in less than a decade. The growth of CHI-X is also partly attributed to ASIC and the RBA. Following ASX platform crashes in 2020 causing outage for almost a full day of trading ASIC and RBA probed the need for less reliance on one monopoly. ASX Shares: Company Reports ASX shares released their Half-Yearly report in February 2021. Highlights: EBIT up 1.3% to $319.1m; however, interest earnings reduced due to lower rates – NPAT down 3.4% to $241.8m. Operating revenue up 3.4% to $470.5m – growth in listings and equity activities balancing downturn in futures. Solid result achieved in mixed conditions reflecting strength of diversified business. Higher capital investment reflecting long-term transformation of technology and operations. Lower interim dividend in line with reduced NPAT – down 3.4% to 112.4cps – 90% payout ratio maintained. Thanks for Reading Full Analysis if Interested: ASX Analysis Prophet Invest
  10. Massive Moves in 2021 Highlights Jumbo Interactive shares reached new 52 week highs over the last few weeks. Current Market Cap and Fundamentals Jumbo Shares (JIN ASX) currently trade on the Australian Stock Exchange at a price of $15.08/share and a market cap of $941million. Jumbo Shares are still down about 50% since their all time highs of over $27 a share back at the end of 2019. Trading Update Half Year December 2020 Jumbo Interactive delivered modest gains of 9% for their Half Year revenue. However, NPAT were trending down 8.6%. This is slightly disappointing. However, its worthwhile remembering that this is likely due to the lotto cycle. This half deliver only 15 large jackpot as compared to 23 in the PCP. Jumbo announced a fully franked interim dividend of 18c per JIN Shares. Gatherwell Gaining Traction Jumbo’s Acquisition of UK based business Gatherwell seems to be gaining traction with Gatherwell UK achieving their first earn-out milestone as at 9th November 2020. Gatherwell posted in incredible EBITDA growth of 107%, revenue growth of 26% like-for-like half year. Jumbo Shares Cash Position Jumbo has a Cash position of $61.9 million dollars as at 31 Dec 2020. Net Assets are $81.85million Full Article: https://prophet-invest.com/massive-moves-in...e-jin-asx"]Visit My Website[/url]
  11. Good luck to all investors
  12. ART is severely under capital and doesn't have enough revenues to grow and pay its debts. I think we will see constant capital raises for the time being. A cap raise 3 month after IPO is evident of this. https://prophet-invest.com/airtaskerasxart-...-a-trading-halt
  13. On Friday IMU reached a 10-year high of $160.50. Today the Imugene share price is $0.405. The current share price is up 1091% from 1-year, and 3987% over the last 5-years. I just wanted to point out this isn’t an all-time high as reported. The group reported a loss for the period ended 31 December 2020 of $6,062,737. This increased loss is largely due to the significant increase in clinical trial and research activities undertaken by the group. The group’s net assets increased to $63,063,057 compared with $59,806,343 at 30 June 2020, including cash reserves of $32,832,479. https://prophet-invest.com/imugene-limited-...hanging-company Visit My Website At it’s current state IMU is well funded to continue research and trials. Although overtime capital raising will likely be necessary. It’s no question Imugene is hoping to disrupt the cancer treatment space. We hope it does. This could mean massive improvements compared to invasive cancer treatments in use today.
  14. Afterpay is a stock that relies heavily on momentum. The biggest upcoming price catalyst for Afterpay is their potential US listing. Moving to the US will significantly improve APT’s access to capital and help facilitate the massive expansion of the BNPL giant onto global scales we have never seen. Afterpay is very similar in scale to US BNPL giant, Affirm. Comparing their financials it’s surprising how similar these companies are. APT is trading at a premium to Affirm in market cap. https://prophet-invest.com/should-i-buy-apt-shares
  15. "CBA is also focusing on the changing market by entering into the Buy-Now Pay-Later (BNPL) space with its 5.5% stake in BNPL giant Klarna" Klarna is still going ahead. This is new on top of Klarna. Big news for CBA i think, very innovative company https://prophet-invest.com/should-i-buy-cba-shares
  • Create New...